Physician profile
Michael Scott Roundy
NPI 1255366696
$4,046.01
in general payments reported to CMS, 2019-2025
19 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $503 · 2021: $887 · 2022: $808 · 2023: $705 · 2024: $968 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,582.39 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $598.02 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $379.79 | 2020-2024 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $374.94 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $241.11 | 2021-2024 | Sublocade |
| Neurocrine Biosciences, INC. | $177.22 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $133.27 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $128.90 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $126.30 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $68.08 | 2022-2024 | Austedo Xr |
| Neuronetics, INC. | $57.05 | 2024-2025 | Neurostar Tms Therapy System |
| Braeburn INC. | $52.27 | 2023-2024 | Brixadi |
| Medline Industries Lp | $42.88 | 2025 | |
| Sumitomo Pharma America, INC. | $30.58 | 2023 | Latuda |
| Tris Pharma INC | $20.11 | 2024 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.05 | 2024 | Abilify Asimtufii, Abilify Maintena |
| Noven Therapeutics, LLC | $15.05 | 2024 | Xelstrym |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.